Non-Alcoholic Fatty Liver Disease. Nonalcoholic steatohepatitis (NASH)
Conditions
Interventions
Intervention 1: Intervention group 1 silymarin: Silymarin 140 mg BID (with the brand name of Livergol from Goldaru Pharmaceutical Company, Iran) for four months.Additionally, they were all given consu
Sponsors
Shahid Sadoughi University of Medical Sciences-Yazd, Iran
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: The inclusion criteria were : NAFLD confirmed through abdominal ultrasonography, persistent elevation in the level of alanine aminotransferase (ALT) within the last six months for one and a half times more than the upper normal limit, fatty changes diagnosed through ultrasonography, and over 20 years of age.
Exclusion criteria
Exclusion criteria: The exclusion criteria were autoimmune hepatitis, alpha-1 antitrypsin deficiency, chronic hepatitis B or C, hemochromatosis, and Wilson’s disease. Patients with a history of diabetes, daily consumption ethanol, severe cardiac, pulmonary, renal, or psychological problems, positive pregnancy test, and the use of drugs such as statins, fibrates, anti-convulsants, NSAID, acetaminophen, warfarin, metronidazole, anti-depressants, or anti-psychotics were also excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ALanin aminotransferas measurements. Timepoint: They were received at the baseline and then after four months for ALT measurements. Method of measurement: autoanlizer.;Ultrasonographic evaluations of their liver. Timepoint: first and four months later. Method of measurement: General Electric ultrasound device,. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactmohsen akhondi-Meybodi
Yazd University of Medical Sciences
Outcome results
None listed